Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Viruses are obligate intracellular parasites that make use of the host metabolic machineries to meet their biosynthetic needs, identifying the host pathways essential for the virus replication may lead to potential targets for therapeutic intervention. The mechanisms and pathways explored by SARS-CoV-2 to support its replication within host cells are not fully known. Lipid droplets (LD) are organelles with major functions in lipid metabolism and energy homeostasis, and have multiple roles in infections and inflammation. Here we described that monocytes from COVID-19 patients have an increased LD accumulation compared to SARS-CoV-2 negative donors. In vitro , SARS-CoV-2 infection modulates pathways of lipid synthesis and uptake, including CD36, SREBP-1, PPARγ and DGAT-1 in monocytes and triggered LD formation in different human cells. LDs were found in close apposition with SARS-CoV-2 proteins and double-stranded (ds)-RNA in infected cells. Pharmacological modulation of LD formation by inhibition of DGAT-1 with A922500 significantly inhibited SARS-CoV-2 replication as well as reduced production of pro-inflammatory mediators. Taken together, we demonstrate the essential role of lipid metabolic reprograming and LD formation in SARS-CoV-2 replication and pathogenesis, opening new opportunities for therapeutic strategies to COVID-19.
Article activity feed
-
-
SciScore for 10.1101/2020.08.22.262733: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Ethics statement: Experimental procedures involving human cells from healthy donors were performed with samples obtained after written informed consent and were approved by the Institutional Review Board (IRB) of the Oswaldo Cruz Foundation/Fiocruz (Rio de Janeiro, RJ, Brazil) under the number 397-07.
IRB: Experimental procedures involving human patient cells were performed with samples obtained after written informed consent from all participants or patients’ representatives according to the study protocol approved by the National Review Board (CONEP 30650420.4.1001.0008).Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a … SciScore for 10.1101/2020.08.22.262733: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Ethics statement: Experimental procedures involving human cells from healthy donors were performed with samples obtained after written informed consent and were approved by the Institutional Review Board (IRB) of the Oswaldo Cruz Foundation/Fiocruz (Rio de Janeiro, RJ, Brazil) under the number 397-07.
IRB: Experimental procedures involving human patient cells were performed with samples obtained after written informed consent from all participants or patients’ representatives according to the study protocol approved by the National Review Board (CONEP 30650420.4.1001.0008).Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable After 2 hours of the plaque, non-adherent cells were washed out and the remaining monocytes were maintained for 24 hours in DMEM containing 5% inactivated male human AB serum (HS; Merck) and 100 U/mL penicillin-streptomycin (P/S; GIBCO) at 37 °C in 5 % CO2. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources The cells were incubated with anti-CD14 antibodies (1:10) for 10 min and magnetic beads-conjugates (1:20) for additional 10 min, followed by magnetic recovery of monocytes for 5 min. anti-CD14suggested: NoneThe purity of human monocytes was above 90 %, as analyzed by flow cytometry analysis (FACScan; Becton Dickinson) using anti-CD3 (BD Biosciences) and anti-CD16 (Southern Biotech) monoclonal antibodies. anti-CD3suggested: Noneanti-CD16suggested: NoneThe double-RNA was labeling by mouse monoclonal antibody J2 clone - Scicons (Schönborn et al., 1991) at 1:500 dilution for overnight, followed by a mouse anti-IgG-Dylight 550 at 1:1000 dilution for 1h. anti-IgG-Dylight 550suggested: NoneMembranes were probed overnight with the following antibodies: anti-PPARγ (Santa Cruz Biotechnology, #SC-7196 - H100), anti-CD36 (Proteintech-18836-1-AP), anti-SREBP-1 (Ab-28481), anti-DGAT-1 (Santa Cruz Biotechnology, #SC-271934) and anti-β-actin (Sigma, #A1978). anti-PPARγsuggested: (Enogene Cat# E2A6073, RRID:AB_2861246)anti-CD36suggested: Noneanti-SREBP-1suggested: Noneanti-DGAT-1suggested: None#SC-271934suggested: (Santa Cruz Biotechnology Cat# sc-271934, RRID:AB_10649947)anti-β-actinsuggested: NoneExperimental Models: Cell Lines Sentences Resources Human lung epithelial carcinoma cell line (A549 - ATCC/CCL-185) and African green monkey kidney (Vero subtype E6) were cultured in high glucose DMEM supplemented with 10% FBS and 100 U/mL P/S, and were incubated at 37 °C in 5 % CO2. A549suggested: NoneThe Plaque-forming Assay was performed for virus titration in VERO E6 cells seeded in 24-well plates. VERO E6suggested: NoneLipid droplet staining: Human primary monocytes, A549 cell line, and HMVEC cell line were seeded in coverslips. HMVECsuggested: NoneSoftware and Algorithms Sentences Resources The numbers of LDs were automatically quantified by ImageJ software analysis from 15 aleatory fields. ImageJsuggested: (ImageJ, RRID:SCR_003070)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-